FPT Achieves 2024 EcoVadis Platinum Rating for Sustainability Through Its French Subsidiary
12.12.2024 08:24:00 CET | Business Wire | Press release
Global technology corporation FPT recently achieved the EcoVadis Platinum rating through its French subsidiary. This is the highest distinction in the survey conducted by EcoVadis, an international organization that evaluates corporate sustainability activities. The recognition places FPT in the top 1% of companies evaluated worldwide for their commitment to sustainable business practices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211227891/en/
(Graphic: Business Wire)
The EcoVadis rating is a comprehensive assessment of a company’s environmental, social, and governance (ESG) practices. It includes a global network of over 130,000 companies of various sizes across 220+ industries and 180+ countries. Sustainability performance is assessed across 21 criteria in four themes: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement.
FPT attained an overall score of 88/100, with impressive ratings of 90/100 for both Labor & Human Rights and Ethics, and 80/100 for the Environment category. This achievement reflects the company’s commitment to all dimensions of environmental policies, efficient corporate governance protocols, robust employee professional development initiatives, and dedication to reducing carbon emissions.
Mdm. Chu Thi Thanh Ha, Chairwoman of FPT Software, FPT Corporation, said: “FPT’s recognition by EcoVadis comes as part of our broader sustainability strategy, which includes embracing technologies, cultivating future-ready talents and driving new values that will last generations. Moving forward, we will continue to prioritize sustainability across all levels of our operations, with ongoing initiatives and investments to integrate sustainable practices into our solutions and services, as well as the work we deliver to our global customers.”
In 2023, FPT received a Silver rating from EcoVadis, further demonstrating its dedication to sustainable and ethical practices. In 2024, the company achieved ISO 45001 certification, the international standard for occupational health and safety, across its twelve campuses and offices in Vietnam, Germany, and France. Additionally, FPT won the Job Creation Award at ESGBusiness Awards 2024 and joined the Pledge 1% movement, reinforcing its dedication to corporate social responsibility and community engagement.
Since entering France in 2008, FPT has solidified its market position and demonstrated its expertise by collaborating with global leaders such as Airbus, La Poste, Air Liquide, Quadient, etc. In 2023, the French subsidiary entered France's top 100 ICT Companies. That same year, the company further strengthened its capabilities by acquiring an 80% stake in French IT consulting firm AOSIS, enhancing its expertise in SAP, Data, Cloud, and smart solutions tailored for the aerospace, aviation, and transportation industries. Looking ahead, FPT aims to be among the Top 50 IT companies in France, targeting to expand its local workforce to over 500 experts and its presence in France and neighbouring Francophone countries.
About FPT
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of USD 2.17 billion and 48,000+ employees. For more information about global IT services, please visit https://fptsoftware.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211227891/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom